1998
DOI: 10.2165/00003495-199856010-00013
|View full text |Cite
|
Sign up to set email alerts
|

Nelfinavir

Abstract: Nelfinavir-based combination regimens are well tolerated and produce profound and prolonged suppression of HIV replication in adult and paediatric patients. Hence, nelfinavir is suitable for inclusion in antiretroviral regimens for initial therapy for HIV infection and, alternatively, in regimens for patients unable to tolerate other protease inhibitors.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
16
0

Year Published

1999
1999
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 81 publications
(16 citation statements)
references
References 29 publications
0
16
0
Order By: Relevance
“…Nelfinavir is a selective inhibitor of HIV protease, which is responsible for posttranslational processing of HIV propeptides. 106 Yamamoto et al 107 had found that nelfinavir could strongly inhibit the replication of SARS-CoV. Therefore, nelfinavir could also be an option for the treatment of COVID-19.…”
Section: Nelfinavirmentioning
confidence: 99%
“…Nelfinavir is a selective inhibitor of HIV protease, which is responsible for posttranslational processing of HIV propeptides. 106 Yamamoto et al 107 had found that nelfinavir could strongly inhibit the replication of SARS-CoV. Therefore, nelfinavir could also be an option for the treatment of COVID-19.…”
Section: Nelfinavirmentioning
confidence: 99%
“…A unique mutation of the protease gene confers resistance. Diarrhoea is the most frequently reported adverse event in patients receiving nelfinavir-based combination therapy, together with rash, nausea, headache and asthenia Nelfinavir is metabolised by the cytochrome P450 system [27]. Although less effective than other PIs, nelfinavir is positioned as an alternative agent for the treatment of adults and adolescents with HIV infection and is an option for those unable to tolerate other protease inhibitors, as well as in pregnant and paediatric patients with HIV infection, due to prolonged viral suppression, good tolerability, a unique resistance profile [28,29].…”
Section: Hiv-1 Pismentioning
confidence: 99%
“…However, diarrhea of moderate to severe intensity can occur in patients receiving multi-drug therapy [21-23]. The mechanisms underlying antiretroviral-induced diarrhea are unclear.…”
Section: Discussionmentioning
confidence: 99%